CLAIM SUBSTANTIATION

In vitro tests

- **Activation of intracellular adenyl cyclase**

  Pleurimincyl™ increases cyclic AMP production by 133%.

- **Lipolytic effect on adipocytes**

  3% Pleurimincyl™ stimulates glycerol release by up to 265%.

In vitro



In vivo tests

- **Demonstration of the lipolytic effect**

  16 panellists.

  Daily application (on the thighs) of an emulsion containing 3% Pleurimincyl™ versus placebo for 8 weeks.

  Measurements of the adipose tissue thickness by echography.

- **Sensory evaluation**

  62.5% of the panellists reported a visible slimming and firming effect and a decrease of cellulite.

In vivo

Demonstration of the lipolytic effect



After 8 weeks, the thickness of the adipose tissue decreases by 6% (1.9 mm) as compared to TO

Formulation

Slimming Gel
with Pleurimincyl™ and Keratoline™

Formulation Ref.: SED09910023I

Part A	**%**
Ultrez 10 *(Carbomer, B F Goodrich)*	0.50
Deionized water	6.00

Part B	**%**
PEG-400 *(PEG-8)*	5.00
Carraghenan	0.50
Preservative	qs

Part C	**%**
Water deionised	50.05
Potassium sorbate	0.10
Sodium Disulfite	0.05

Part D	**%**
Pemulen TR1 *(C 10-30 Alkyl Acrylate Crosspolymer, B F Goodrich)*	0.20
D 345 *(Cyclomethicone, Dow Corning)*	4.00

Part E	**%**
Menthol	0.10
Alcohol	20.00

Part F	**%**
Deionized water	7.00
Sodium hydroxide 30%	0.70

Part G	**%**
PLEURIMINCYL™ *(Sederma)*	3.00
Keratoline® *(Sederma)*	2.00

Protocol

Disperse Ultrez 10 into water and let swell for 15 minutes (part A). Mix ingredients of part B. Weigh part C and mix it with part B. Add part A to Part B+C. Mix ingredients of part D. Add part D to part A+B+C and let swell for 1 hour. Mix ingredients of part E and add it to part A+B+C+D. Homogenise. Neutralise with part F. Then add part G.

Non-warranty: This formulation has been subjected to limited stability tests and has been shown to perform well. However formulators adopting this approach should ensure to their own satisfaction long term stability and functionality. It is good practice to conduct safety tests on all final formulations prior to marketing. Suggested uses should not be taken as an inducement to infringe any existing patents.

Sederma Inc. email: sederma-usa@croda.com - www.crodausa.com tel.: 732-692-1652 fax: 732-417-0804